FBX-101
Phase 2Gene therapy
FBX-101 is one of 3 biologic programs targeting Krabbe disease. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Krabbe Disease
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Busulfex
Akero TherapeuticsApproved
FBX-101
FForge Biologics, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FBX-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Gene therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- FForge Biologics, Inc